Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.3412 -0.0010 (-0.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,227,406
Open 0.3511
Bid (Size) 0.2910 (1)
Ask (Size) 0.3150 (40)
Prev. Close 0.3422
Today's Range 0.3401 - 0.3600
52wk Range 0.2900 - 1.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Independent Directors of 23andMe Resign from Board
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire

Performance

YTD
-62.44%
-62.44%
1 Month
-5.12%
-5.12%
3 Month
-16.56%
-16.56%
6 Month
-27.56%
-27.56%
1 Year
-66.55%
-66.55%

More News

Read More
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
From 23andMe, Inc.
Via GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
From 23andMe, Inc.
Via GlobeNewswire
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025
Via InvestorPlace
23andMe Reports First Quarter Fiscal 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
Via InvestorPlace
23andMe Special Committee responds to CEO’s take-private proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
From 23andMe, Inc.
Via GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
From Kahn Swick & Foti, LLC
Via Business Wire
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Via InvestorPlace
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
From 23andMe, Inc.
Via GlobeNewswire
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
Via The Motley Fool
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
23andMe Launches New Genetic Report on Bipolar Disorder
From 23andMe, Inc.
Via GlobeNewswire
Why 23andMe Stock Tumbled 10% on Tuesday
Via The Motley Fool
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
Privacy Policy  |  Terms of Use  |  MNG Corporate Site Map  |  Copyright